ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).

Supportive Care

Symptom Management

Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Survivorship

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD, on Reduction of Late Mortality in Childhood Cancer Survivors

Lisa Diller, MD, of Dana-Farber Cancer Institute, and Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discuss the findings of a landmark survivorship study (Abstract LBA2).

Prostate Cancer

Christopher Sweeney, MBBS

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).

Prostate Cancer

Christian Carrie, MD and Celestia S. Higano, MD

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).

Sep

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD, on Reduction of Late Mortality in Childhood Cancer Survivors

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

FDA Grants Zanubrutinib Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

Survey Examines Oncology Clinician Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer

Inclusion of Women in Oncology Clinical Trials From 2000 to 2020

Atezolizumab Plus Chemotherapy in Patients With Advanced NSCLC and Brain Metastases

Almost Two-Thirds of Thoracic Oncologists Reported Using Telehealth for the First Time During the COVID-19 Pandemic